

SECURITIES AND EXCHANGE COMMISSION

FORM 3

Filing Date: **2011-02-03** | Period of Report: **2011-01-31**
SEC Accession No. **0001140361-11-006207**

([HTML Version](#) on [secdatabase.com](#))

REPORTING OWNER

Blachman Amir

CIK: **1509562**

Type: **3** | Act: **34** | File No.: **000-53071** | Film No.: **11572294**

Mailing Address

*TARGETED MEDICAL
PHARMA, INC.
2980 BEVERLY GLEN CIRCLE,
SUITE 301
LOS ANGELES CA 90077*

ISSUER

Targeted Medical Pharma, Inc.

CIK: **1420030** | IRS No.: **412254388** | State of Incorpor.: **DE** | Fiscal Year End: **1209**
SIC: **6770** Blank checks

Mailing Address

*2980 BEVERLY GLEN CIRCLE
SUITE 301
LOS ANGELES CA 90077*

Business Address

*2980 BEVERLY GLEN CIRCLE
SUITE 301
LOS ANGELES CA 90077
310-474-9809*

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL	
OMB Number:	3235-0104
Expires:	02/28/2011
Estimated average burden hours per response	0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person <u>Blachman Amir</u> (Last) (First) (Middle) C/O TARGETED MEDICAL PHARMA, INC., 2980 BEVERLY GLEN CIRCLE, SUITE 301 (Street) LOS ANGELES, CA 90077 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 01/31/2011	3. Issuer Name and Ticker or Trading Symbol <u>Targeted Medical Pharma, Inc. [NONE]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below) <u>VP of Strategy and Operations</u>	5. If Amendment, Date Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check applicable line) <input checked="" type="checkbox"/> Form Filed by One Reporting Person <input type="checkbox"/> Form Filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Options to Purchase Common Stock	05/16/2010	05/16/2020	Common Stock	7,395	\$3.38	D	
Options to Purchase Common Stock	(1)	07/28/2020	Common Stock	73,945	\$3.38	D	

Explanation of Responses:

1. These options vest monthly in equal installments over a two-year period from the date of grant. 22,800 of such options are currently vested.

Signatures

/s/ Amir Blachman

** Signature of Reporting Person

01/31/2011

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.